Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 27, 2026, titled "Glenmark Pharmaceuticals Inc., USA to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has informed the stock exchange about a press release dated February 27, 2026. Through its US subsidiary, Glenmark Pharmaceuticals Inc., USA, the company will launch Sodium Phosphates Injection USP in three strengths: 15 mM P/5 mL, 45 mM P/15 mL, and 150 mM P/50 mL (3 mM P/mL), packaged in single-dose vials. Sodium Phosphates Injection is commonly used in hospital and clinical settings as a saline laxative for bowel preparation before procedures or for treating constipation. The launch is aimed at the US generic injectables market and adds to the company's existing portfolio of injectable products in the United States.
This product expansion in the US market is a positive development that could support incremental revenue from Glenmark's US generics business. However, since sodium phosphates injection is a commodity generic product in a competitive category, the stock price impact is likely to be limited unless the product captures meaningful market share.